DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4s8jdj/global_dna) has announced the addition of the "Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering.
The global DNA diagnostics market would reach $19 billion by 2020 registering a CAGR of 9.8% from 2014 to 2020
The potential to provide accurate diagnosis and cost effectiveness over alternative diagnostic techniques are factors which supplement the growth of the DNA diagnostics market. AMR analysis suggests that the tremendous potential of novel DNA diagnostic technologies and the probability of them being adopted in personalized medicines has not only reduced the expenditure in diagnostic procedures but has also helped in increasing the efficiency of chronic disease identification.
Furthermore, the emergence of personalized medicines and the rising number of initiatives vis-à-vis product development and clinical trials from key players has laid the groundwork for DNA diagnostics technologies. Various technologies such as PCR, sequencing technology, microarray, in situ hybridization and mass spectrometry are considered in this report, with special emphasis on key market trends and their growth potential. Given its wide scope of application in almost all activities related to DNA diagnostics, the polymerase chain reaction (PCR) technology holds the largest share of DNA diagnostics market revenue.
Market analysis in terms of geography suggests that developed economies would retain their dominance in the market. This could be attributed to the early adoption of the technology due to potential reduction offered by DNA diagnostic to their high healthcare expenditure. However, developing economies, such as in Asia-Pacific, will significantly influence the DNA diagnostic market during the extended forecast period (2020-2025), largely due to potential growth in per capita healthcare expenditure and very large undiagnosed population.
Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenantal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market.
Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott Laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.
Scope of the Report
MARKET BY PRODUCT TYPE
- Instruments
- Reagents
- Service & Software
MARKET BY TECHNOLOGY
- PCR
- Microarray
- In-situ Hybridization
- Sequencing Technology
- Mass Spectrometry
- Others
MARKET BY APPLICATION
- Oncology
- - Prostate Cancer
- - Breast Cancer
- - Colorectal Cancer
- - Others
- Infectious Disease
- - Hepatitis B Virus
- - Hepatitis C Virus
- - HIV
- - TB
- - Chlamydia Trachomatic and Neisseria Gonorrhea (CT/NG)
- - HPV
- - Methiciline Resistant Staphylococcus Aureus (MRSA)
- - Others
- Myogenic Disorder
- Clinical Diagnostic Confirmation
- Prenatal Diagnostics
- Pre-implantation Diagnostics
- Others
MARKET BY END USERS
- Point of Care
- Diagnostic Center
- Self Testing/OTC
For more information visit http://www.researchandmarkets.com/research/4s8jdj/global_dna
